Activation-Induced Expression of Human Programmed Death-1 Gene in T-Lymphocytes

doi:10.1006/excr.1997.3493

Experimental Cell Research

Volume 232, Issue 1, 10 April 1997, Pages 25-28

https://doi.org/10.1006/excr.1997.3493 Get rights and content

Abstract

The Programmed Death-1 (PD-1) gene is a member of the immunoglobulin superfamily of genes. Murine PD-1 mRNA expression has been shown to correlate with activation-induced apoptosis in a mouse T-cell hybridoma cell line and in murine thymocytes. Here we report that expression of the human homolog, hPD-1, seems to correlate with activation of T lymphocytes rather than apoptosis. We observed a time-dependent upregulation of hPD-1 mRNA and protein levels in Jurkat cells during phorbol ester (12-O-tetradecanoylphorbol 13-acetate, TPA)-induced differentiation. Human PD-1 protein was also induced during lectin-stimulated activation of human peripheral blood mononuclear cells. Additionally, TPA stimulation of Jurkat cells induces tyrosine phosphorylation of hPD-1, putatively on its cytoplasmic tail signal transduction motif. These data suggest a role for hPD-1 during activation and differentiation of T-lymphocytes.

References (15)

T. Cotner et al.
J. Exp. Med.
(1983)
T. Lindsten et al.
J. Immunol.
(1993)
C. Liu et al.
Biochem. J.
(1995)
J.P. Allison et al.
Science
(1995)
Y. Ishida et al.
EMBO J.
(1992)
L. R. Finger, J. Pu, R. Wasserman, R. Vibhakar, E. Louie, R. R. Hardy, P. D. Burrows, L. G. Billips,...
T. Shinohara et al.
Genomics
(1994)

There are more references available in the full text version of this article.

Cited by (125)

Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma
2020, Critical Reviews in Oncology/Hematology
Citation Excerpt :
As a supplement to the current research system, this paper reviews the multi-dimensional nature of the PD-1/PD-L1 axis regarding immune cell infiltration into the GBM tumour microenvironment (TME), as well as the recent progress in preclinical and clinical research. In the setting of GBM, PD-1 is expressed on T cells, B cells, tumour-associated macrophages (TAMs), MDSCs, and NK cells (Agata et al., 1996; Nam et al., 2019; Pesce et al., 2017; Vibhakar et al., 1997; Wang et al., 2019b), suggesting that PD-1 expression is a universal phenomenon involved in the innate and adaptive arms of the immune systems that takes part in forming the suppressive tumour environment. PD-L1 is located on the surface of glioma cells and is simultaneously expressed in TAMs, B cells and MDSCs (Kohanbash and Okada, 2012; Lee-Chang et al., 2019; Pardoll, 2012).
Glioblastoma (GBM) is the most common malignant tumour in the brain, and current treatments are not curative and cannot control recurrence. This limitation indirectly places immunotherapy at the focus of translational GBM research. Many studies on the PD-1/PD-L1 axis in GBM are ongoing, and the immunosuppressive mechanism of PD-1/PD-L1 in GBM is different from that in other solid tumours. This review focuses on the effect of the PD-1/PD-L1 axis on infiltrating immune cells in the suppressive GBM immune microenvironment and summarizes the recent progress in PD-1/PD-L1 axis-related therapies reported in preclinical and clinical GBM studies, providing a reference for the systematic study of PD-1/PD-L1 axis-related anti-GBM immunity.
Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis
2020, American Journal of the Medical Sciences
There is a growing interest in using programmed death ligand-1 (PD-L1) as a prognostic marker for melanoma. We conducted this meta-analysis to explore the prognostic and clinicopathological value of PD-L1 in melanoma.
The electronic databases PubMed, Web of Science and the Cochrane Library were searched for relevant studies. The major investigated parameters were PD-L1 expression levels in relation to patient gender, tumor-infiltrating lymphocytes (TILs), tumor stage, lymph node (LN) metastasis, histological type, progression-free survival (PFS) and overall survival (OS). Odds ratios (ORs) and hazard ratios (HRs) were computed using the fixed-effect or random-effects model according to data heterogeneity.
Positive PD-L1 expression was significantly associated with high levels of TILs (OR = 7.56, 95% CI 2.04-28.02), metastatic melanoma (OR = 0.45, 95% CI 0.30-0.67) and LN-positive melanoma (OR = 2.56, 95% CI 1.31-4.99) but not gender or histological type. In addition, the pooled HRs showed no relation between PD-L1 expression and PFS (HR = 1.18, 95% CI 0.83-1.69) or OS (HR = 0.77, 95% CI 0.47-1.25). When restricted to metastatic melanoma, positive PD-L1 expression was significantly related to prolonged OS (HR = 0.57, 95% CI 0.46-0.70).
Positive PD-L1 expression may be an important prognostic factor for longer OS in patients with metastatic melanoma.
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
2019, Drug Resistance Updates
Citation Excerpt :
Understanding how PD-L1 expression on tumor cells is regulated through crosstalks with other signaling pathways may aid in developing new drug targets and combination therapies to reverse the resistance of cancers to immunotherapies. PD-1 is expressed on activated T lymphocytes and plays a role in the inactivation of T cells (Vibhakar et al., 1997; Hutten et al., 2018; Brunner-Weinzierl and Rudd, 2018). The absence of PD-1 on T-cells leads to enhanced generation of CD4/CD8 double-negative peripheral T-cells, suggesting a role for PD-1 in thymic development (Blank et al., 2003; Verstichel et al., 2017).
Recent advances in the treatment of various cancers have resulted in the adaptation of several novel immunotherapeutic strategies. Notably, the recent intervention through immune checkpoint inhibitors has resulted in significant clinical responses and prolongation of survival in patients with several therapy-resistant cancers (melanoma, lung, bladder, etc.). This intervention was mediated by various antibodies directed against inhibitory receptors expressed on cytotoxic T-cells or against corresponding ligands expressed on tumor cells and other cells in the tumor microenvironment (TME). However, the clinical responses were only observed in a subset of the treated patients; it was not clear why the remaining patients did not respond to checkpoint inhibitor therapies. One hypothesis stated that the levels of PD-L1 expression correlated with poor clinical responses to cell-mediated anti-tumor immunotherapy. Hence, exploring the underlying mechanisms that regulate PD-L1 expression on tumor cells is one approach to target such mechanisms to reduce PD-L1 expression and, therefore, sensitize the resistant tumor cells to respond to PD-1/PD-L1 antibody treatments. Various investigations revealed that the overexpression of the transcription factor Yin Yang 1 (YY1) in most cancers is involved in the regulation of tumor cells’ resistance to cell-mediated immunotherapies. We, therefore, hypothesized that the role of YY1 in cancer immune resistance may be correlated with PD-L1 overexpression on cancer cells. This hypothesis was investigated and analysis of the reported literature revealed that several signaling crosstalk pathways exist between the regulations of both YY1 and PD-L1 expressions. Such pathways include p53, miR34a, STAT3, NF-kB, PI3K/AKT/mTOR, c-Myc, and COX-2. Noteworthy, many clinical and pre-clinical drugs have been utilized to target these above pathways in various cancers independent of their roles in the regulation of PD-L1 expression. Therefore, the direct inhibition of YY1 and/or the use of the above targeted drugs in combination with checkpoint inhibitors should result in enhancing the cell-mediated anti-tumor cell response and also reverse the resistance observed with the use of checkpoint inhibitors alone.
cGAS-STING and PD1/PDL-1 pathway in breast cancer: a window to new therapies
2024, Journal of Receptors and Signal Transduction
Expression and clinical implications of HLA-G and PD-L1 following kidney transplantation: A cohort study
2023, Medicine (United States)
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma
2023, Cancer Immunology, Immunotherapy

View all citing articles on Scopus

¹: To whom correspondence and reprint requests should be addressed at Cancer Research Institute at New York Medical College, 100 Grasslands Road, Elmsford, NY 10523. Fax: (914) 347-2804. E-mail: [email protected].

View full text

Regular ArticleActivation-Induced Expression of Human Programmed Death-1 Gene in T-Lymphocytes

Abstract

J. Exp. Med.

J. Immunol.

Biochem. J.

Science

EMBO J.

Genomics

Regular Article
Activation-Induced Expression of Human Programmed Death-1 Gene in T-Lymphocytes